Rein Therapeutics, Inc. Balance Sheet
RNTX|9 years of annual SEC 10-K data (FY2017-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 9 fiscal years. All figures from audited SEC 10-K filings.
Rein Therapeutics, Inc. had $24M in total assets and $54M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.9M | $17.3M | $17.3M | $5.2M | $3.6M | $7.0M | $5.3M | $10.6M | $11.9M |
| Current Assets | $4.3M | $13.7M | $18.3M | $21.9M | $48.2M | $16.3M | $19.6M | $21.8M | $51.8M |
| PP&E (Net) | - | $1.0K | $19.0K | $70.0K | $128.0K | $15.0K | $295.0K | $7.3M | $154.0K |
| Goodwill | $6.3M | $6.3M | $6.3M | - | - | - | - | - | - |
| Total Assets | $24.2M | $62.2M | $106.0M | $22.0M | $48.5M | $16.3M | $26.5M | $30.3M | $52.7M |
| Current Liabilities | $6.2M | $5.7M | $4.4M | $3.4M | $4.5M | $4.0M | $5.8M | $5.4M | $4.9M |
| Shareholders' Equity | $54.4M | $98.3M | $18.6M | $43.9M | $12.2M | $16.0M | $19.6M | $47.8M | -$111.8M |